首页> 美国卫生研究院文献>Computational and Structural Biotechnology Journal >Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19
【2h】

Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19

机译:抗氧化剂和偏毒素作为辅助标准治疗的措施改善Covid-19肺炎患者预后的措施

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The type 2 coronavirus causes severe acute respiratory syndrome (SARS-CoV-2) and produces pneumonia with pulmonary alveolar collapse. In some cases it also causes sepsis and septic shock. There is no specific treatment for coronavirus disease 2019 (COVID-19). Vitamin C (Vit C), Vitamin E (Vit E), N-acetylcysteine (NAC) and Melatonin (MT) increase the intracellular content of GSH, kidnap free radicals and protect DNA, proteins in the cytosol and lipids in cell membranes. Pentoxifylline (Px) has anti-inflammatory activities. Here we evaluate the effect of Vit C, Vit E, NAC, and MT plus Px in COVID-19 patients with moderate and severe pneumonia. 110 patients of either sex were included. They were divided into five groups with 22 patients each. Group 1 received Vit C + Px, group 2 Vit E + Px, group 3 NAC + Px, group 4 MT + Px, and group 5 only Px. Oxidative stress (OS) markers such as lipid peroxidation (LPO) levels, total antioxidant capacity (TAC) and nitrites (NO2–) were evaluated in plasma. The antioxidant therapy improved the survival scores including the Sequential Organ Failure Assessment (SOFA), the Acute Physiology and chronic Health Evaluation II (Apache II), the Simplified Acute Physiology Score II (SAPS II), the Critical Illness Risk Score, Launched during COVID-19 crisis (COVIDGRAM) and the Glasgow Coma Scale (GCS). We found that LPO (p≤0.04) and inflammation markers such as interleukin-6 (IL-6, p≤ 0.01), C reactive protein (CRP, p ≤ 0.01) and procalcitonin (PCT, p ≤ 0.05) were elevated. TAC (p ≤ 0.03) and NO2– (p ≤ 0.04) found themselves diminished in diminished in COVID-19 patients upon admission to the hospital. The different antioxidants reversed this alteration at the end of the treatment. The treatment with antioxidant supplements such as Vit C, E, NAC, and MT plus Px could decelerate the aggressive and lethal development of COVID-19. Antioxidant therapy can be effective in this pandemia since it improves the survival scores including SOFA, Apache II, SAPS II, COVIDGRAM, GCS by lowering the LPO, IL-6, CRP, PCT and increasing systemic TAC and NO2–.
机译:2型冠状病毒导致严重的急性呼吸综合征(SARS-COV-2),并产生肺部肺泡塌陷的肺炎。在某些情况下,它还会导致败血症和脓毒性休克。 2019年(Covid-19)的冠状病毒疾病没有具体治疗。维生素C(VIT C),维生素E(VIVE),N-乙酰半胱氨酸(NAC)和褪黑激素(MT)增加了GSH,绑扎自由基的细胞内含量,并保护DNA,在细胞膜中的细胞溶胶和脂质中的蛋白质。 pentoxifylline(px)具有抗炎活动。在这里,我们评估vit C,Vit E,NAC和MT Plus PX在Covid-19中度和严重肺炎的患者中的影响。包括任何性别的110名患者。它们分为五组,每个患者每组22例。第1组接受vit C + PX,第2组Vit E + PX,第3组NAC + PX,4 MT + PX和第5组仅限PX。在血浆中评价氧化应激(OS)诸如脂质过氧化(LPO)水平,总抗氧化能力(TAC)和亚硝酸盐(NO 2-)的标记。抗氧化治疗改善了包括顺序器官衰竭评估(沙发),急性生理学和慢性健康评估II(Apache II)的存活率,简化的急性生理学得分II(SAPS II),在Covid期间发射的临界疾病风险评分-19危机(Covidgram)和Glasgow Coma Scale(GCS)。我们发现LPO(P≤0.04)和炎症标记如白细胞介素-6(IL-6,P≤0.01),C反应蛋白(CRP,P≤0.01)和ProCalcitonin(PCT,P≤0.05)升高。 TAC(p≤0.03)和NO2-(p≤0.04)发现本身在Covid-19患者入院时减少了在院内减少。不同的抗氧化剂在治疗结束时逆转了这种改变。用抗氧化剂补充剂如VIT C,E,NAC和MT Plus PX处理可以减少Covid-19的侵袭性和致命的发育。抗氧化治疗可以在这种羽裤血症中有效,因为它通过降低LPO,IL-6,CRP,PCT和增加全身TAC和NO2-,因此它可以改善包括沙发,Apache II,SAPS II,Covidgram,GCS的存活评分。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号